Solving Drug Discovery at Scale
Drug discovery has long been defined by decade-long timelines, billion-dollar costs, and high failure rates. WeDaita is changing that — with AI agents built to compress timelines, cut costs, and improve decision quality at every stage of the pipeline.
90%
Failure Rate
9 in 10 drug candidates fail — most due to poor target validation and inadequate early-stage evidence. WeDaita's DBRA agents surface higher-confidence targets from the start.
10–15
Years per Drug
A decade-plus of research, design, and trials before patients see results. WeDaita compresses the early discovery pipeline from years to weeks.
$2–3B
Per Drug Candidate
Billions spent per approved drug — driven by inefficiency and late-stage failures. WeDaita reduces the cost burden by cutting wasted research cycles early.
BioMedAI Platform
One Platform. Full Discovery Pipeline.
Three agent modules that cover the complete drug discovery workflow — from target to candidate.
Stage 1 — Early Research
DBRA
Deep Biomedical Research Agents
6 Agents Live
Solves the Haystack Problem — automating evidence synthesis to generate and validate novel drug targets — in minutes, not days or weeks.
- Deep Research Assistant
- Disease Hypothesis Generation
- Drug Target Prioritization
- Drug Repurposing
- Competitive Landscape
- Biomarker Discovery
100×
Reduction in early research time
Stage 2 — Drug Design
ADDA
Autonomous Drug Design Agents
1 Agent Live
Bridges the Translation Gap — automating biologic and small molecule drug design to reduce preclinical failure rates.
- Protein / antibody drug design
- Peptide/MacrocycleIn Dev
- Small molecule design & optimisationIn Dev
10×
Faster drug design cycles
Stage 3 — Clinical Trials
CTIA
Clinical Trial Intelligence Agents
1 Agent Live
Addresses Late-Stage Attrition — AI-assisted protocol design, predictive recruitment, and portfolio optimization.
- Pharmacovigilance
- Predictive patient recruitmentRoadmap
- AI-assisted protocol designRoadmap
- Portfolio optimizationRoadmap
- Digital twin trial simulationRoadmap
200×
Faster clinical trial execution
See BioMedAI in Action
See how BioMedAI DBRA agents deliver trusted biomedical insights through intelligent AI agents
- Plug-and-play biomedical AI via WeDaita MCP services
- High-confidence insights from verified medical and clinical databases
- Rapid literature review and clinical trial intelligence
- Seamless agent-tool integration with zero local installation
The Team Behind BioMedAI
Scientists, engineers, and domain experts united by one mission — making drug discovery faster and smarter.
Wenliang Zhang, PhD, MMed
Founder, CEO/CTO
- Director of Data Science: Pfizer, Exo Therapeutics
- Principal Data Engineer: AbbVie
- Principal Software Engineer: PerkinElmer, Akoya Bio
- Computational Biologist: Bluebird Bio, Tesaro
Chao Yang, PhD
AI/ML Computational Chemistry Advisor
- PhD in Chemistry, New York University
- Postdoc Research, The Rockefeller University
- Computational Chemistry: Axle Informatics, Exo Therapeutics
- AI-guided Virtual Screening and Drug Design
Elena Chernokalskaya, Ph.D
Mentor and Growth Advisor
- Founder, Boston Business Mentor
- Certified Counselor, SCORE Mentors
- Scientific Advisory Board, 908 Devices
- Executive, Cytiva & GE Helathcare
- Proteomics Group Leader, Vertex Pharmaceuticals
Latest from WeDaita
News & Blog
Company updates, tutorials, and community posts — all in one place.
Attended the Agentic Immunology Summit this past Thursday.
With nearly 10 years hands-on experience in immunology research during my PhD and postdoc training, and over a decade working in AI/ML across biotech and pharma, this meeting felt like the perfect intersection of two fields I care deeply about.
Read more
🚀 Selected for Harvard Business School Foundry Bootcamp — Advancing AI for Drug Discovery
Excited and honored to share that I’ve been selected for the Harvard Business School Foundry Bootcamp! 🚀 A program bringing together deep and tough tech founders to further develop and validate investor-ready ventures.
Read more
BioMedAI 2.0 Beta is officially live!
If you are a researcher working in drug discovery and struggling with the haystack problem, BioMedAI can accelerate your breakthrough from target to candidate with absolute confidence.
Read more
AI Won't Replace Scientists — But It Will Replace Workflows
The debate about AI replacing scientists is a distraction. The real disruption is quieter: the elimination of the low-value workflows that eat most of a scientist's week.
Read · 6 min
What We Learned Building an Agentic AI Platform for Drug Discovery
The hard lessons from building DBRA, ADDA, and CTIA: why most AI drug discovery tools don't survive contact with real biology, and what we changed.
Read · 9 min
Tips and Tricks of self-host gitlab setup
Set up your Gitlab give you completely control on how your code version control and CICD process. A practical notes to self-hosting GitLab with the Omnibus image—covering setup, port and proxy configuration, SSH access, Web IDE fixes, CI/CD best practices, and Docker registry tweaks.
Read · 2 min
Stay Ahead
AI Drug Discovery, Delivered Monthly
Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.
No spam. Unsubscribe at any time. We respect your privacy.
Ready to Accelerate Your Drug Discovery?
BioMedAI is live — start with target identification and protein drug design today, with more modules launching soon.